IR@PKUHSC  > 北京大学第一临床医学院  > 肾脏内科
学科主题临床医学
Pros and cons for C4d as a biomarker
Cohen, Danielle1; Colvin, Robert B.2; Daha, Mohamed R.3; Drachenberg, Cinthia B.4; Haas, Mark5; Nickeleit, Volker6; Salmon, Jane E.7; Sis, Banu8; Zhao, Ming-Hui9; Bruijn, Jan A.1; Bajema, Ingeborg M.1
关键词Acute Allograft Rejection Chronic Rejection Complement Transplantation Transplant Pathology
刊名KIDNEY INTERNATIONAL
2012-04-01
DOI10.1038/ki.2011.497
81期:7页:628-639
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Urology & Nephrology
研究领域[WOS]Urology & Nephrology
关键词[WOS]ANTIBODY-MEDIATED REJECTION ; RENAL-ALLOGRAFT REJECTION ; DONOR-SPECIFIC ANTIBODIES ; KIDNEY-TRANSPLANT RECIPIENTS ; COMPLEMENT ACTIVATION ; HUMORAL REJECTION ; GLOMERULAR C4D ; PERITUBULAR CAPILLARIES ; LUPUS NEPHRITIS ; HLA ANTIBODIES
英文摘要

The introduction of C4d in daily clinical practice in the late nineties aroused an ever-increasing interest in the role of antibody-mediated mechanisms in allograft rejection. As a marker of classical complement activation, C4d made it possible to visualize the direct link between anti-donor antibodies and tissue injury at sites of antibody binding in a graft. With the expanding use of C4d worldwide several limitations of C4d were identified. For instance, in ABO-incompatible transplantations C4d is present in the majority of grafts but this seems to point at ′graft accommodation′ rather than antibody-mediated rejection. C4d is now increasingly recognized as a potential biomarker in other fields where antibodies can cause tissue damage, such as systemic autoimmune diseases and pregnancy. In all these fields, C4d holds promise to detect patients at risk for the consequences of antibody-mediated disease. Moreover, the emergence of new therapeutics that block complement activation makes C4d a marker with potential to identify patients who may possibly benefit from these drugs. This review provides an overview of the past, present, and future perspectives of C4d as a biomarker, focusing on its use in solid organ transplantation and discussing its possible new roles in autoimmunity and pregnancy. Kidney International (2012) 81, 628-639; doi:10.1038/ki.2011.497; published online 1 February 2012

语种英语
WOS记录号WOS:000301847900005
引用统计
被引频次:73[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56399
专题北京大学第一临床医学院_肾脏内科
作者单位1.Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
2.Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands
3.Leiden Univ, Med Ctr, Dept Immunol & Renal Dis, NL-2300 RC Leiden, Netherlands
4.Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
5.Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA
6.Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA
7.Hosp Special Surg, Weill Cornell Med Coll, New York, NY 10021 USA
8.Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2M7, Canada
9.Peking Univ, Hosp 1, Dept Med, Div Renal, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Cohen, Danielle,Colvin, Robert B.,Daha, Mohamed R.,et al. Pros and cons for C4d as a biomarker[J]. KIDNEY INTERNATIONAL,2012,81(7):628-639.
APA Cohen, Danielle.,Colvin, Robert B..,Daha, Mohamed R..,Drachenberg, Cinthia B..,Haas, Mark.,...&Bajema, Ingeborg M..(2012).Pros and cons for C4d as a biomarker.KIDNEY INTERNATIONAL,81(7),628-639.
MLA Cohen, Danielle,et al."Pros and cons for C4d as a biomarker".KIDNEY INTERNATIONAL 81.7(2012):628-639.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Cohen, Danielle]的文章
[Colvin, Robert B.]的文章
[Daha, Mohamed R.]的文章
百度学术
百度学术中相似的文章
[Cohen, Danielle]的文章
[Colvin, Robert B.]的文章
[Daha, Mohamed R.]的文章
必应学术
必应学术中相似的文章
[Cohen, Danielle]的文章
[Colvin, Robert B.]的文章
[Daha, Mohamed R.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。